Betsy Garratt, DO
Neurology · Cleveland, OHNPI 1144545864
Payments from drug & device makers
Across 43 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$293
- Argenx US, Inc.$56
- Lilly USA, LLC$52
- Novartis$39
- AstraZeneca$38
- MDD US Operations, LLC$32
- plus $186 from 10 others
What the payments were for
- Food & beverage$64092%
- Education$568%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $293 |
| Argenx US, Inc. | 1 | $56 |
| Lilly USA, LLC | 3 | $52 |
| Novartis | 2 | $39 |
| AstraZeneca | 2 | $38 |
| MDD US Operations, LLC | 2 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| GE HealthCare | 3 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $17 |
| UCB, Inc. | 1 | $16 |
| Sanofi | 1 | $16 |
| Strongbridge US Inc. | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $12 |
| Saol Therapeutics Inc. | 1 | $12 |
How this compares
$696 in reported general payments places this provider in the 40th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 41 | $53,736 |
| AptiomEslicarbazepine Acetate | 13 | $15,846 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $10,054 |
| Oxcarbazepine | 78 | $6,165 |
| Entacapone | 11 | $4,497 |
| Pyridostigmine Bromide | 41 | $4,282 |
| Memantine Hcl | 95 | $3,832 |
| Memantine Hcl ErMemantine Hcl | 17 | $3,707 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 115 | $2,871 |
| Propranolol Hcl ErPropranolol Hcl | 49 | $2,592 |
| Primidone | 90 | $2,582 |
| Lacosamide | 31 | $2,523 |
| Levetiracetam | 74 | $2,394 |
| Carbamazepine ErCarbamazepine | 12 | $2,000 |
| Gabapentin | 91 | $1,932 |
Paid to pharmacies, not to this prescriber.
Other neurology in Cleveland
- Robert BermelCleveland$6.4M
- Jeffrey CohenCleveland$3.1M
- Yuebing LiCleveland$1.4M
- Devon ConwayCleveland$1.3M
- Robert FoxCleveland$1.3M
- Glen StevensCleveland$1.1M
- Hubert FernandezCleveland$1.1M
- Hesham AbboudCleveland$1.1M
- Michal GostkowskiCleveland$850K
- Daniel OntanedaCleveland$838K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.